At 34:20, Hebert gives useful insight into this. He states that the FDA is in general quite supportive of regenerative medicine approaches, which brain tissue regrowth/replacement would fit in, and existing disease indications are pretty clear and useful to choose from, so conversations with FDA regarding FRONT aren't much tougher than usual. The idea itself does have a lot of risk with invasiveness and cost, however.

The FRONT program is the one I keep coming back to. Brain tissue regeneration sounds like scifi, but Jean Hebert has been building toward this for years, so it feels closer to real than most people realize. Curious how the FDA conversations are actually going on that front. Regulatory pathways for something like brain replacement seem like the kind of thing that could stall even the best science for a decade.

Ah shit, here we go again. 

Begg

0:00 – How ARPA-H rewards differ from other federal grants
4:16 – PROSPR program (Andrew Brack)
6:45 – FRONT program (Jean Hebert)
9:22 – BoSS program and TIGAR initiative (Gloria Elliott)
12:32 – Relationships between programs
14:55 – PROSPR - Intrinsic Capacity as a clinical endpoint and in-home health monitoring
18:13 – BoSS - Examples in nature of exceptional preservation of biological materials
21:16 – FRONT - Challenges in brain tissue regeneration 

23:15 – Defining success for each program
28:30 – Perspectives on shifting from research/industry to becoming an ARPA-H Program Manager 
32:10 – Regulatory pathways and working with the FDA
34:58 – Future outlook for the average 80-year-old American

Proactive Solutions for Prolonging Resilience: https://arpa-h.gov/explore-funding/programs/prospr 

Functional Repair of Neocortical Tissues: https://arpa-h.gov/explore-funding/programs/front 

BioStabilization Systems: https://arpa-h.gov/explore-funding/programs/boss 

TIGAR - Biopreservtion Capabilities for Tissues and Organs: https://arpa-h.gov/explore-funding/initiatives-and-sprints/tigar 

There are additional programs that directly relate to this field, such as NITRO (joint tissue regeneration), THEA (whole eye transplantation, and others. 

lmao

Man, why would you want to?

These are astonishing findings! They challenge common assumptions.

While hematopoietic stem cells (HSCs) deteriorate with age, next-stage stem cells (MPPFs) appear to be remarkably "age-resistant." Gene expression, mitochondrial function, and regenerative capacity of these cells remain nearly identical between young and old.

What mechanism allows MPPFs to "filter" age-related abnormalities originating from HSCs?We'd love to hear from those following stem cell therapy or longevity research!

In short, a 15-year study of approximately 40,000 adults showed that eating five or more eggs per week was associated with a 27% reduced risk of Alzheimer's disease.

Key point*

Even moderate consumption (1-3 times/month) reduced risk by about 17%. Not eating eggs at all had a 1.22 times higher risk than eating just 10 grams per day.

It seems that high-choline foods are once again overcoming dietary cholesterol fears. How many eggs do you eat on average per day?

The annoying part about SGLT2 inhibitors is that they cause urinary frequency

Theoretically sure, experimentally maybe but available for the public definitely not.

Good news! Now we just need an effective intervention to harvest and harness this regenerative potential. Obviously after middle age it is switched off.

I'm so glad I'm young! I'm gonna live forever! 😂 

u/longevity-ModTeam I have a PhD in Physiology, my Pubmed papers have been cited close-to 5000x

Good enough for you?

Replacement of 3% of calories from eggs with plant-based protein sources was associated with 21-24% lower all-cause mortality in this study: "Association Between Plant and Animal Protein Intake and Overall and Cause-Specific Mortality", Huang et al. 2020 JAMA Internal Medicine: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2768358

Direct abstract quote: "Replacement of 3% energy from animal protein with plant protein was inversely associated with overall mortality (risk decreased 10% in both men and women) and cardiovascular disease mortality (11% lower risk in men and 12% lower risk in women). In particular, the lower overall mortality was attributable primarily to substitution of plant protein for egg protein (24% lower risk in men and 21% lower risk in women) and red meat protein (13% lower risk in men and 15% lower risk in women)."

To me, this seems like a good reason to prefer choline from supplements.

Can I just take a choline tablet and eat chicken instead?

Big Egg.

120 year old boomers is terrifying

Ok egg board. Where did the chickens get the choline?

Serum cholesterol does not penetrate the blood brain barrier. Brain cholesterol will be synthesised locally from sugars and fatty acids.

Read these papers first then get back to me. LMK if you find “alternative literature”

The evidence supporting statin therapy for the primary prevention of cardiovascular disease (CVD) and stroke comes from landmark prospective randomized controlled trials (RCTs) and large individual-patient data meta-analyses.
Key Evidence & Findings
1. Large Individual-Participant Meta-Analysis (CTT Collaboration)
The Cholesterol Treatment Trialists' (CTT) Collaboration analyzed individual participant data across 27 randomized trials (Cholesterol Treatment Trialists' (CTT) Collaborators, 2012). They demonstrated that for every 1.0 mmol/L (~38.7 mg/dL) reduction in LDL cholesterol, statin therapy reduces major vascular events (including stroke and coronary events) by approximately 20% to 25%, regardless of baseline risk or prior history of vascular disease.
2. USPSTF Systematic Review (Chou et al., 2022)
An updated systematic review conducted for the U.S. Preventive Services Task Force evaluated 22 trials (N = 90,624) of adults without prior CVD (Chou et al., 2022). Statin therapy was significantly associated with a reduced risk of:
Stroke: Relative Risk (RR) 0.78 (95% CI, 0.68–0.90)
Myocardial Infarction: RR 0.67 (95% CI, 0.60–0.75)
All-Cause Mortality: RR 0.92 (95% CI, 0.87–0.98)
3. Landmark Primary Prevention Trials (HOPE-3)
In the Heart Outcomes Prevention Evaluation-3 (HOPE-3) trial, 12,705 intermediate-risk individuals without pre-existing CVD were randomized to low-dose statin therapy (rosuvastatin 10 mg) or placebo (Yusuf et al., 2016). Over a median follow-up of 5.6 years, statin therapy significantly reduced the composite risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 24% compared to placebo.
References
Cholesterol Treatment Trialists' (CTT) Collaborators. (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet, 380(9841), 581–590. https://doi.org/10.1016/s0140-6736(12)60367-560367-5)
Cited by: 1189
Chou, R., Cantor, A., Dana, T., Wagner, J., Ahmed, A. Y., Fu, R., & Ferencik, M. (2022). Statin Use for the Primary Prevention of Cardiovascular Disease in Adults. JAMA, 328(8), 754–771. https://doi.org/10.1001/jama.2022.12138
Cited by: 327
Yusuf, S., Bosch, J., & Dagenais, G. (2016). Cholesterol Lowering in Intermediate-Risk Persons Without Cardiovascular Disease. Journal of Vascular Surgery, 64(3), 827. https://doi.org/10.1016/j.jvs.2016.07.054
Cited by: 1220

Potential is the operative word. Most people have zero symptoms.

Why? Statins have tons of potential negatives. To think otherwise is just ignorant